Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca To "Go It Alone" For Crestor, Cites Large Market Opportunity

Executive Summary

AstraZeneca will pursue a solo marketing strategy for Crestor (rosuvastatin) based on the larger market outlined in recently issued cholesterol treatment guidelines.

You may also be interested in...



AstraZeneca Boosts Sales Productivity: Physician Office Calls Up 50%

AstraZeneca's Crestor launch will help push sales representative office visits to more than seven calls a day, a 50% increase over 2001, Senior VP-Commercial Operations Tony Zook told analysts

AstraZeneca Boosts Sales Productivity: Physician Office Calls Up 50%

AstraZeneca's Crestor launch will help push sales representative office visits to more than seven calls a day, a 50% increase over 2001, Senior VP-Commercial Operations Tony Zook told analysts

AstraZeneca Crestor NDA Includes Rhabdomyolysis Reports At Highest Dose

AstraZeneca's discussions with FDA about the safety profile of the experimental cholesterol drug Crestor (rosuvastatin) are focusing on the potential for the highest dose to cause rhabdomyolysis, the company indicated during analysts meetings the week of Dec. 3

Related Content

UsernamePublicRestriction

Register

PS038240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel